Benefits
Helps reduce joint pain and stiffness
Several randomized trials of green-lipped mussel preparations in adults with osteoarthritis of the hip and knee report reductions in pain and stiffness, though systematic reviews have judged the overall evidence mixed and not fully consistent. It is studied to support joint comfort over weeks to months of use.
Supports a healthy inflammatory response
The unique marine omega-3 fatty acid profile in green-lipped mussel, including ETA and furan fatty acids, is thought to support a balanced inflammatory response, consistent with the joint symptom changes reported in some human trials.
Helps support exercise recovery
In untrained men undergoing muscle-damaging exercise, daily PCSO-524 supplementation attenuated markers of muscle damage and reduced delayed-onset muscle soreness, supporting use as part of an exercise recovery strategy.
Supports joint mobility and function
Beyond pain reduction, green-lipped mussel trials report improvements in joint function and range of motion scores, supporting easier movement and day-to-day mobility in adults with osteoarthritis.
Provides marine omega-3 fatty acid support
Green-lipped mussel naturally supplies EPA, DHA, and the rarer eicosatetraenoic acid (ETA), complementing dietary omega-3 intake from fish or algae as part of overall omega-3 nutrition.
Mechanism of action
5-lipoxygenase and inflammatory pathway modulation
Lipid components of green-lipped mussel, including ETA and other omega-3 fatty acids, modulate cyclooxygenase and 5-lipoxygenase pathways and reduce production of pro-inflammatory leukotrienes and prostaglandins in joint tissues.
Specialized pro-resolving mediator support
Marine omega-3 fatty acids from green-lipped mussel serve as substrates for resolvins and protectins that actively resolve inflammation, complementing the suppression of pro-inflammatory mediators.
Cartilage and connective tissue support
Naturally occurring glycosaminoglycans and proteoglycan-related components in green-lipped mussel support chondrocyte function and cartilage matrix integrity in preclinical joint models.
Muscle damage and inflammation attenuation
PCSO-524 supplementation reduces post-exercise increases in skeletal muscle slow troponin I, TNF-alpha, myoglobin, and creatine kinase, supporting attenuation of exercise-induced muscle damage and inflammation.
Clinical trials
Multicenter 2-month open-label (uncontrolled, non-placebo) clinical trial of Lyprinol (PCSO-524) at 2 capsules twice daily in patients with hip and knee osteoarthritis.
60 patients with symptomatic osteoarthritis of the knee and hip.
After 4 and 8 weeks of treatment, 53% and 80% of patients respectively experienced significant pain relief and improvement of joint function. In this uncontrolled, open-label trial patients reported symptom improvement and good tolerability; the lack of a control group limits how much can be concluded.
Randomized human trial of 3,000 mg/day whole green-lipped mussel extract powder vs 3,000 mg/day glucosamine sulphate for 12 weeks.
Adults with knee osteoarthritis.
Both interventions provided meaningful improvements in joint symptoms over 12 weeks, with green-lipped mussel powder showing comparable benefit to glucosamine and concurrent shifts in gastrointestinal microbiota profiles.
Randomized placebo-controlled trial of 1,200 mg/day PCSO-524 for 26 days pre- and 96 hours post-muscle-damaging downhill running.
32 untrained adult male subjects.
PCSO-524 significantly attenuated skeletal muscle slow troponin I, TNF-alpha, myoglobin, and CK-MM at multiple timepoints, reduced delayed-onset muscle soreness at 72 and 96 hours, and lessened strength and joint range of motion loss compared with placebo.